Clinical observation of pirarubicin combined with cyclophosphamide in the treatment of non Hodgkin's lymphoma
10.3760/cma.j.issn.1008-6706.2014.02.020
- VernacularTitle:吡柔比星联合环磷酰胺治疗非霍奇金淋巴瘤的临床观察
- Author:
Huiling ZHENG
- Publication Type:Journal Article
- Keywords:
Pirarubicin;
Chemotherapy;
Non Hodgkin's lymphoma
- From:
Chinese Journal of Primary Medicine and Pharmacy
2014;21(2):204-206
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of pirarubicin combined with cyclophosphamide chemotherapy in the treatment of non Hodgkin's lymphoma.Methods 70 cases with non Hodgkin's lymphoma were randomly divided into the observation group and control group,35 cases in each group.The observation group was treated with pirarubicin chemotherapy,the control group received doxorubicin chemotherapy scheme.The clinical efficacy and side effects of the two groups were observed.Results The effective rate of the observation group was 74.3％,which was significantly higher than 51.4％ of the control group (x2 =6.28,P ＜ 0.05).The bone marrow suppression,nausea,vomiting,abnormal liver function and other side effects between the two groups had no significant differences (x2 =1.62,0.52,0.00,all P ＞ 0.05).The incidence rates of alopecia and ECG abnormality in the observation group were 31.4％ and 11.4％,which were significantly lower than 100.0％,34.3％ of the control group (x2 =36.52,5.19,all P ＜ 0.05).Conclusion The clinical efficacy of pirarubicin combined with cyclophosphamide chemotherapy is satisfactory,its main advantage is obviously decreased heart toxicity and alopecia.
